Patents by Inventor Ruling ZHANG

Ruling ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12780859
    Abstract: Provided is the novel class of platinum compounds shown in formula (I), and their use as pharmaceutical agents, especially for treating cancer alone or in combination and for preventing cancer. The described novel platinum compounds have been shown, through experimentation, to have superior in vivo antitumor effects, significantly better than the clinical drug carboplatin, and to have significantly improved the aqueous solubility of platinum-based drugs, and can be made into lyophilized powder or injectable solution, resolving the defect of inconvenient clinical use. In view of the foregoing, the disclosed class of platinum compounds has good prospects for clinical application.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: November 3, 2026
    Assignee: SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventor: Ruling Zhang
  • Publication number: 20230339997
    Abstract: Provided is the novel class of platinum compounds shown in formula (I), and their use as pharmaceutical agents, especially for treating cancer alone or in combination and for preventing cancer. The described novel platinum compounds have been shown, through experimentation, to have superior in vivo antitumor effects, significantly better than the clinical drug carboplatin, and to have significantly improved the aqueous solubility of platinum-based drugs, and can be made into lyophilized powder or injectable solution, resolving the defect of inconvenient clinical use. In view of the foregoing, the disclosed class of platinum compounds has good prospects for clinical application.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 26, 2023
    Inventor: Ruling Zhang
  • Patent number: 10301325
    Abstract: Disclosed are a quinoline derivative, and a pharmaceutical composition, a preparation method and a use thereof. The quinoline derivative of the present invention has a c-Met inhibitory activity and can be used for the treatment, relieving and/or prevention of cancers or similar diseases.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 28, 2019
    Assignee: SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventor: Ruling Zhang
  • Publication number: 20180244695
    Abstract: Disclosed are a quinoline derivative, and a pharmaceutical composition, a preparation method and a use thereof. The quinoline derivative of the present invention has a c-Met inhibitory activity and can be used for the treatment, relieving and/or prevention of cancers or similar diseases.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 30, 2018
    Inventor: Ruling ZHANG